Chemical Biology and Drug Design

JANUARY 29, 2024

sPLA 2 inhibitors have been developed for the treatment of inflammatory and other conditions such as cardiovascular disease, arteriosclerosis and rheumatoid arthritis. Besides their roles in the degradation of phospholipids, these enzymes also play an important role in the immune response by promoting inflammation.

Small Molecule 100

Small Molecule Immune Response Treatment Disease 100

SugarCone Biotech

MARCH 24, 2025

These agents simultaneously bind to a tumor-associated protein on cancer cells and the CD3 protein on T-cells, facilitating a targeted anti-cancer immune response. Other mechanisms that cancer cells use to escape from TCE treatment are less expected. Today, however, we turn to the TCE therapeutic class.

Immune Response 67

Immune Response Therapies Treatment Disease 67

Drug Target Review

APRIL 17, 2024

HLA are the critical molecules that our immune systems use to present peptides to T cells and facilitate recognition and killing in immune responses to pathogens. HLA-II presents peptides to CD4 T cells thought to be important for indirectly helping immune responses and facilitating antibody production.

Immune Response 105

Immune Response Laboratories DNA Virus 105

The Pharma Data

OCTOBER 26, 2020

Food and Drug Administration (FDA) has approved EYSUVIS for the short-term treatment of dry eye disease. . EYSUVIS is the first FDA-approved corticosteroid specifically for dry eye disease treatment. Over-the-counter treatments fail due to the body’s natural protective system. 25% for dry eye disease treatment.

Treatment 52

Treatment Disease FDA FDA Approval 52

PLOS: DNA Science

FEBRUARY 8, 2024

The molecular tools of CRISPR were borrowed and developed from the natural immune response of bacteria to viruses – bacteriophages – that infect them. Beef production Add a gene conferring a short, slick coat that enables cattle to tolerate heat. But will it, can it, improve upon nature?

Immune Response 97

Immune Response DNA Engineering Virus 97

Olympian Clinical Research

NOVEMBER 16, 2022

HS is believed to develop due to an immune response that generates too much inflammation. People with HS may have an overactive immune system, which causes their bodies to overreact to the presence of a blocked hair follicle. Treatments for Hidradenitis Suppurativa. It’s also not caused by poor hygiene. Procedures.

Treatment 52

Treatment Clinical Research Immune Response Therapies 52

The Pharma Data

APRIL 15, 2022

We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals.

Immune Response 52

Immune Response Vaccine Clinical Trials Virus 52

Conversations in Drug Development Trends

JUNE 21, 2024

Worldwide Clinical Trials attends each year to hear from the research community, connect with our sponsors and sites, and explore potential partnerships to drive forward novel treatments. Its primary challenges include: Production Delays : The time-intensive process of expanding TILs to therapeutic quantities poses logistical hurdles.

Clinical Trials 64

Clinical Trials Therapies Clinical Research Immune Response 64

The Pharma Data

DECEMBER 17, 2020

San Diego-based Janux Therapeutics forged a strategic collaboration with pharma giant Merck potentially worth more than $1 billion to develop next-generation T cell engager immunotherapies for the treatment of cancer. Janux technology can be applied to immunotherapies that target all three stages of an anti-tumor immune response.

Immune Response 52

Immune Response Pharmacokinetics Engineering Licensing 52

The Pharma Data

SEPTEMBER 25, 2020

The data demonstrate that a single dose of JNJ-78436735 induced a strong neutralizing antibody response in nearly all participants aged 18 years and older and was generally well-tolerated. Immune responses were similar across the age groups studied, including older adults. Immune Response Data.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

OCTOBER 23, 2020

A solidarity clinical trial “is one of the largest international randomized trials for Covid-19 treatments, enrolling almost 12,000 patients in 500 hospital sites in over 30 countries”, according to the World Health Organization (WHO), which launched the trail with a number of partners. Source link.

Trials 52

Trials Immune Response Hospitals Clinical Trials 52

The Pharma Data

SEPTEMBER 3, 2020

The data, published today in Nature Medicine , demonstrated that the Company’s investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited an immune response as demonstrated by “neutralizing antibodies” and prevented severe clinical disease – including weight loss, pneumonia and mortality – in Syrian golden hamsters upon challenge.

Vaccine 52

Vaccine Disease Immune Response Pharmaceutical Companies 52

The Pharma Data

NOVEMBER 17, 2020

Located in Oss, the Netherlands, Lead Pharma is a clinical-stage biopharmaceutical company focused on the development of novel small-molecule therapies for patients suffering from autoimmune diseases (a subset of immune-mediated diseases) and cancer. . Our ambition is to develop life-changing treatments for patients.

Small Molecule 52

Small Molecule Disease Immune Response Licensing 52

The Pharma Data

DECEMBER 23, 2020

Inotrem’s Phase IIa clinical trial, which takes place in France, Belgium and the United States will determine the safety, tolerability and potential signals of efficacy of nangibotide, the company’s lead product, in critically ill COVID-19 patients. PARIS–( BUSINESS WIRE )– Inotrem S.A., Marc Derive. www.inotrem.com.

Clinical Trials 52

Clinical Trials Trials Research Immune Response 52

The Pharma Data

JANUARY 18, 2021

Next Generation AAVs enhance gene therapies by increasing transduction efficiency and specificity while reducing immune responses and cost. Both parties aim to build a strategic partnership for long term success which will bring accessible AAV gene therapy treatment to patients around the world.”

Therapies 52

Therapies Immune Response DNA Treatment 52

The Pharma Data

DECEMBER 10, 2020

The vaccine targeted both the inner nucleocapsid (N) and the outer spike (S) proteins of the virus to maximize the immune response. The study showed this broad immune response led to the complete clearance of the virus in a matter of days after infection of previously-vaccinated primates. and its affiliate NantKwest, Inc.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

PerkinElmer

MAY 6, 2022

Coined immunotherapy, this umbrella term describes several types of treatment, including immune checkpoint inhibitors, immune system modulators, and adoptive cell therapies. Each triggers the immune system in a different way to fight cancer.

Immune Response 52

Immune Response DNA Clinical Trials Engineering 52

The Pharma Data

JUNE 26, 2021

In line with our global leadership and our 7 0-year history of pro tecting people with influenza v accine s , w e will always focus on developing product s that demonstrate protection beyond flu , as we believe it is critical to demonstrate protecting patients from hospitalizations due to cardiovascular events and pneumonia.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

JANUARY 12, 2021

“The T-cell and NK-cell target discovery approach complements our portfolio aimed at turning cold tumors hot and redirecting the innate immune system to elicit a sustained and durable immune response against tumors. KSQ is also eligible to receive tiered royalties on net sales of each approved product.

Therapies 52

Therapies Immune Response Research Engineering 52

The Pharma Data

JANUARY 3, 2021

. Both will help NexImmune advance current early-stage clinical trials and will guide Company’s translational efforts to develop new immunotherapy products. It is my privilege to advise NexImmune as it seeks to develop novel treatments for melanoma and other cancers,” stated Dr. Weber. GAITHERSBURG, Md.,

Immune Response 40

Immune Response Clinical Trials Therapies Cell Biology 40

The Pharma Data

MARCH 11, 2021

Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. Efforts are also underway to enable the product to be stable at routine refrigerator temperature (2-8°C). Expected to enroll 415 participants; interim results expected in Q3 2021.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

SEPTEMBER 8, 2021

While these results are disappointing, w e believe th e rilzabrutinib clinical program holds great potential to address the unmet treatment needs of people living with immune-mediated diseases , ” said Naimish Patel, Head of Global Development, Immunology and Inflammation. “

Immune Response 52

Immune Response Trials Treatment Disease 52

The Pharma Data

NOVEMBER 9, 2020

Additionally, the vast majority of patients only receive a temporary benefit or no benefit from ICIs, as they either develop resistance to the treatment during the course of therapy or are non-responsive to the treatment altogether (only 15%-20% of patients respond, according to published data). Next Steps in Immunotherapy.

Immune Response 40

Immune Response Therapies Clinical Trials Treatment 40

The Pharma Data

JUNE 17, 2022

In a Phase 2/3 clinical trial, the Pfizer-BioNTech COVID-19 Vaccine elicited a strong immune response in this age group Three 3-µg doses had favorable safety profile similar to placebo in young children ages 6 months through 4 years in Phase 2/3 clinical trial Pfizer-BioNTech COVID-19 Vaccine now authorized in the U.S.

Vaccine 52

Vaccine FDA Clinical Trials Immune Response 52

The Pharma Data

JANUARY 6, 2021

Quantitative imaging of CD8 T cells enables quicker identification of drug efficacy, therefore potentially reducing the length of clinical trials, reducing costs and helping new therapies to advance to market faster, which ultimately will improve treatment and care of cancer patients.

Licensing 52

Licensing Licensing Clinical Trials Pharmaceutical Companies 52

The Pharma Data

JUNE 24, 2021

Secondary objectives are to describe immune responses produced by each of the vaccines. Appropriate medical treatment used to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of Pfizer BioNTech COVID-19 Vaccine. The Pfizer?BioNTech

Vaccine 52

Vaccine Immune Response FDA Licensing 52

The Pharma Data

OCTOBER 21, 2020

T cell therapy expressing a chimeric antigen receptor (CAR) targeting CD20 for treatment of non-Hodgkin’s lymphoma (NHL). T cell products,” said Chen Schor, President and Chief Executive Officer of Adicet. “We We look forward to advancing our product pipeline to address additional solid and hematologic tumors.”. About ADI-001.

FDA 40

FDA Immune Response Clinical Trials Engineering 40

The Pharma Data

DECEMBER 28, 2020

Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Annamycin for treatment of soft tissue sarcomas. .

FDA 52

FDA Clinical Trials Drugs Pharmaceutical Companies 52

Drug Target Review

OCTOBER 17, 2024

While its involvement in the do-not-eat-me signal from cancer has inspired therapeutic development of this pathway for oncology, the function of the innate immune checkpoint we identified in 2009 1 extends to both innate and adaptive immune responses. CD24 and Siglec-10 Selectively Repress Tissue Damage-Induced Immune Responses.

Immune Response 52

Immune Response Clinical Trials Trials Therapies 52

The Pharma Data

DECEMBER 23, 2020

All 38 subjects who were evaluable for immunogenicity had balanced cellular and humoral immune responses following the second dose of INO-4800. The antigen is processed naturally in the cell and triggers the desired T cell and antibody-mediated immune responses. About INOVIO.

DNA 40

DNA Vaccine Clinical Trials Immune Response 40

The Pharma Data

DECEMBER 17, 2020

These follow-on data provided the first definitive prospective evidence demonstrating anti-viral activity for a treatment regimen now available for COVID-19, and also further documented the ability of this treatment to decrease the need for further medical attention,” said George D. Yancopoulos , M.D.,

Hospitals 52

Hospitals Production Clinical Trials Virus 52

The Pharma Data

OCTOBER 28, 2020

. “We continue to see the strongest effects in patients who are most at risk for poor outcomes due to high viral load, ineffective antibody immune response at baseline, or pre-existing risk factors. Serious adverse events were numerically more frequent with placebo than REGN-COV2 treatment (0.8% There was a 1.08

Virus 40

Virus Trials Clinical Trials Production 40

The Pharma Data

NOVEMBER 9, 2020

Specifically, tezepelumab targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic and other types of airway inflammation associated with severe asthma.

Trials 52

Trials Production Clinical Trials Government 52

The Pharma Data

JULY 6, 2021

At ISTH, we are sharing data across all our innovative approaches and collectively, the data reinforce how our pipeline and portfolio may unlock new possibilities in the treatment of rare blood disorders.”. Breaking barriers in hemophilia: helping to evolv e the treatment paradigm. ePoster Abstract # OC48.2 ePoster Abstract # OC48.2

Therapies 52

Therapies Pharmacokinetics Treatment RNA 52

The Pharma Data

JANUARY 31, 2021

While HIV treatment has advanced dramatically over the past three decades, people living with HIV still face a lifetime of therapy,” said Diana Brainard, MD, Senior Vice President, Virology Therapeutic Area, Gilead Sciences. “We This press release features multimedia. View the full release here: [link]. Terms of the Agreement.

Vaccine 52

Vaccine Science Clinical Trials Licensing 52

The Pharma Data

JANUARY 17, 2021

Joe Dupere, CEO of Ixaka, commented: “Ixaka’s broad offering of integrated cell and gene therapy capabilities, encompassing cell-based products and an innovative in vivo gene delivery platform, provides a strong foundation for our ambitions to become a leader in cell and gene therapies.

Therapies 40

Therapies Clinical Trials Disease Immune Response 40

The Pharma Data

FEBRUARY 24, 2022

The Committee considered that the available evidence was sufficient to conclude that the immune response to a booster dose in adolescents would be at least equal to that in adults. Pfizer Inc. No new safety concerns were identified from the data available.

Vaccine 52

Vaccine FDA Small Molecule Immune Response 52